CSBR vs. HUMA, MGTX, PROK, TRML, ALLO, AURA, PRME, KOD, VALN, and CMPX
Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include Humacyte (HUMA), MeiraGTx (MGTX), ProKidney (PROK), Tourmaline Bio (TRML), Allogene Therapeutics (ALLO), Aura Biosciences (AURA), Prime Medicine (PRME), Kodiak Sciences (KOD), Valneva (VALN), and Compass Therapeutics (CMPX). These companies are all part of the "biological products, except diagnostic" industry.
Champions Oncology vs.
Humacyte (NASDAQ:HUMA) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
Humacyte has a net margin of 0.00% compared to Champions Oncology's net margin of -1.12%. Champions Oncology's return on equity of 0.00% beat Humacyte's return on equity.
Humacyte has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.
44.7% of Humacyte shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 11.2% of Humacyte shares are owned by insiders. Comparatively, 47.0% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Champions Oncology received 116 more outperform votes than Humacyte when rated by MarketBeat users. However, 67.31% of users gave Humacyte an outperform vote while only 60.40% of users gave Champions Oncology an outperform vote.
Champions Oncology has higher revenue and earnings than Humacyte. Champions Oncology is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
In the previous week, Humacyte had 6 more articles in the media than Champions Oncology. MarketBeat recorded 8 mentions for Humacyte and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.04 beat Humacyte's score of 0.72 indicating that Champions Oncology is being referred to more favorably in the news media.
Humacyte presently has a consensus target price of $13.71, suggesting a potential upside of 199.44%. Champions Oncology has a consensus target price of $8.00, suggesting a potential downside of 27.19%. Given Humacyte's higher possible upside, analysts clearly believe Humacyte is more favorable than Champions Oncology.
Summary
Humacyte beats Champions Oncology on 9 of the 17 factors compared between the two stocks.
Get Champions Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Champions Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CSBR) was last updated on 2/1/2025 by MarketBeat.com Staff
Free CSBR Stock Alerts